Potassium
Potassium (K)
An essential electrolyte mineral critical for blood pressure regulation, muscle function, nerve signaling, and fluid balance.
Potassium is the primary intracellular cation and one of the most important electrolytes in the body. It's essential for maintaining proper fluid balance, nerve transmission, muscle contraction, and blood pressure regulation. Most people don't get enough potassium from diet alone. Higher potassium intake is strongly associated with lower blood pressure and reduced stroke risk. Works in balance with sodium.
Mechanisms of Action
Blood Pressure Regulation
Promotes sodium excretion and vasodilation
Muscle Function
Essential for muscle contraction
Nerve Signaling
Required for nerve impulse transmission
Recommended Dose
99-500mg daily from supplements (food provides more)
Loading: Not required; get most from food
Optimal Timing
- With food to reduce GI upset
- Spread throughout day
- During/after exercise for athletes
Take with food
Best Form
Potassium Citrate or Potassium Gluconate
Alternatives: Potassium Chloride, Potassium Bicarbonate
Citrate is well-tolerated and may benefit bone health. Chloride is used for deficiency. Most supplements are limited to 99mg.
Duration
Minimum: 4 weeks
Optimal: 12 weeks
Cycling: Not required
Note: Supplements are limited to 99mg per pill by FDA. Most potassium should come from food (bananas, potatoes, leafy greens).
Personalized Dosage Calculator
Get a dosage recommendation tailored to your body weight, age, goals, and health profile.
Set up your health profile for personalized recommendations
Lower Blood Pressure
Significant reduction in blood pressure
Reduced Muscle Cramps
Fewer muscle cramps and better function
Stroke Prevention
Reduced risk of stroke
Hyperkalemia Risk
Too much can be dangerous
AVOID supplementation; potassium can accumulate to dangerous levels
May need more due to sweat losses; replenish during exercise
Who Should NOT Take This
- Kidney disease
- Hyperkalemia
- Use of potassium-sparing diuretics
- Severe Kidney Disease (contraindicated)
Drug Interactions
Risk of dangerous hyperkalemia; avoid combination — may affect electrolyte balance or enhance fluid loss — may affect electrolyte balance or enhance fluid loss
Can increase potassium levels; monitor closely
May increase potassium retention
Risk of dangerous hyperkalemia
Risk of dangerous hyperkalemia
DANGEROUS hyperkalemia, cardiac arrhythmias
Risk of dangerous hyperkalemia, cardiac arrhythmias
Life-threatening hyperkalemia risk
Dangerous hyperkalemia, cardiac arrest risk
Life-threatening hyperkalemia
Complex interaction - both deficiency and excess dangerous
Counteracts therapeutic effect of potassium removal
Possible Side Effects
Tip: Take with food; use slow-release forms
Tip: Monitor if on medications that raise potassium; avoid with kidney disease
Warnings
- Can be dangerous with kidney disease
- Monitor if taking ACE inhibitors or ARBs
- Too much potassium can cause cardiac arrhythmias
Top studies from 40+ peer-reviewed papers
Pillinger T et al. • Lancet (London, England) (2025)
“We found strong evidence that antidepressants differ markedly in their physiological effects, particularly for cardiometabolic parameters.”
Key Findings:
- We found strong evidence that antidepressants differ markedly in their physiological effects, particularly for cardiometabolic parameters.
- Treatment guidelines should be updated to reflect differences in physiological risk, but choice of antidepressant should be made on an individual basis, considering clinical presentation and preferences of patients, carers, and clinicians.
- Further research warranted to confirm findings
Rossignol P et al. • Lancet (London, England) (2025)
“In patients with kidney failure on haemodialysis and with high risk of adverse cardiovascular outcomes, spironolactone did not reduce the incidence of major cardiovascular events.”
Key Findings:
- In patients with kidney failure on haemodialysis and with high risk of adverse cardiovascular outcomes, spironolactone did not reduce the incidence of major cardiovascular events.
- The updated meta-analysis shows that mineralocorticoid receptor antagonists did not reduce all-cause or cardiovascular mortality.
- Therefore, off-label use of spironolactone in this setting is not supported by available evidence.
Natale P et al. • The Cochrane database of systematic reviews (2020)
“Evidence supporting clinical decision-making for different potassium binders to treat chronic hyperkalaemia in adults with CKD is of low certainty; no studies were identified in children.”
Key Findings:
- Patiromer or sodium zirconium cyclosilicate may make little or no difference to death (any cause) (4 studies, 688 participants: RR 0.69, 95% CI 0.11, 4.32; I2 = 0%; low certainty evidence) in CKD.
- Potassium binders may lower serum potassium levels (at the end of treatment) (3 studies, 277 participants: MD -0.62 mEq/L, 95% CI -0.97, -0.27; I2 = 92%; low certainty evidence) in CKD and HD.
- Potassium binders had uncertain effects on constipation (4 studies, 425 participants: RR 1.58, 95% CI 0.71, 3.52; I2 = 0%; low certainty evidence) in CKD.
- Potassium binders may decrease systolic blood pressure (BP) (2 studies, 369 participants: MD -3.73 mmHg, 95%CI -6.64 to -0.83; I2 = 79%; low certainty evidence) and diastolic BP (one study) at the end of the treatment.
Jøns C et al. • The New England journal of medicine (2025)
“Among participants with any cardiovascular disease who had an ICD and were at high risk for ventricular arrhythmias, a treatment-induced increase in plasma potassium levels led to a significantly lower risk of appropriate ICD therapy, unplanned hospitalization for arrhythmia or heart failure, or death from any cause than standard care. (Funded by the Independent Research Fund Denmark and others; POTCAST ClinicalTrials.gov number, NCT03833089.).”
Key Findings:
- Clinical trial examining Potassium efficacy
- Published in The New England journal of medicine (2025)
- Further research warranted to confirm findings
Vardeny O et al. • JAMA cardiology (2025)
“In patients with heart failure with mildly reduced or preserved ejection fraction, finerenone resulted in more frequent hyperkalemia and less frequent hypokalemia.”
Key Findings:
- Finerenone increased the risks of potassium level increasing to greater than 5.5 mmol/L (hazard ratio [HR], 2.16 [95% CI, 1.83-2.56]; P < .001) and decreased the risks for potassium level decreasing to less than 3.5 mmol/L (HR, 0.46 [95% CI, 0.38-0.56]; P < .001).
- Both low (< 3.5 mmol/L; HR, 2.49 [95% CI, 1.8-3.43]) and high (>5.5 mmol/L; HR, 1.64 [95% CI, 1.04-2.58]) potassium levels were associated with higher subsequent risks of the primary outcome in both treatment groups.
- In patients with heart failure with mildly reduced or preserved ejection fraction, finerenone resulted in more frequent hyperkalemia and less frequent hypokalemia.
- However, with protocol-directed surveillance and dose adjustment, clinical benefit associated with finerenone relative to placebo was maintained even in those whose potassium level increased to greater than 5.5 mmol/L.
Study Type Distribution
Goals This Supplement Supports
Related Goals
This information is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any supplement.